LDHA and mesothelioma: However, bench-to-bedside research on hundreds of samples, which clearly improved prognostic capabilities in several tumour types, such as lung or breast cancer, is extremely difficult to achieve in mesotheliomas, which are rare tumours.1 Indeed, most previous candidate biomarkers are based solely on mRNA evidence, and our findings with protein levels in two cohorts of patients, indicate the value of the prognostic value of LDH-A, and should prompt prospective studies for further validation.